LVW Advisors’s BridgeBio Pharma BBIO Stock Holding History

LVW Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$323K	Sell	4,333 -454	-9%	-$31.8K	0.03%	336
2026 Q1	$355K	Buy	4,787 +250	+6%	+$18.1K	0.03%	284
2025 Q4	$347K	Hold	4,537	–	–	0.04%	253
2025 Q3	$236K	Sell	4,537 -130	-3%	-$6.34K	0.02%	314
2025 Q2	$202K	Buy	+4,667	New	+$170K	0.02%	322

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LVW Advisors's BBIO Position: Q2 2026 in Review

LVW Advisors reduced its BridgeBio Pharma (BBIO) stake by 9.5% in Q2 2026, selling an estimated $31.8K and leaving 4,333 shares worth $323K. The position accounts for 0.03% of the portfolio, ranked #336.

LVW Advisors first reported a position in BBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $355K in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

LVW Advisors held 4,333 shares of BridgeBio Pharma worth $323K as of Q2 2026.
LVW Advisors sold 454 BridgeBio Pharma shares in Q2 2026, an estimated $31.8K.
BridgeBio Pharma made up 0.03% of LVW Advisors's portfolio in Q2 2026, its #336 holding.
LVW Advisors first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 5 quarters since.
LVW Advisors's BridgeBio Pharma position peaked at $355K in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on LVW Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.